Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development.
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their toxicities, which are often termed immune-related adverse eve...
| Publicado en: | Clinical Medicine Insights: Oncology pp. 1 - 17 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | algorithm review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
11/24/2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |